<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01953211</url>
  </required_header>
  <id_info>
    <org_study_id>Hormone free interval</org_study_id>
    <nct_id>NCT01953211</nct_id>
  </id_info>
  <brief_title>Oral Contraceptive Hormone-free Interval Pituitary/ Ovarian Activity</brief_title>
  <official_title>LH, FHS, Estradiol and Progesterone Activity During the 7-Day Hormone-Free Interval of Various Combined Oral Contraceptive Regimens</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern California</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The degree of suppression and subsequent activation of the hypothalamic-pituitary-ovarian
      axis during the hormone-free interval in combined oral contraceptive (COC) hormone users
      varies depending on the dose of ethinyl estradiol in the formulation. This variation in
      activation may be associated with different side effects during the hormone free interval.
      Progesterone (P) remained suppressed during all 6 COC regimens (&lt;1.8 ng/mL), which indicates
      continuous contraceptive efficacy during the 7-day hormone free interval of all formulations
      studied.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <primary_completion_date type="Actual">December 1998</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Follicle-stimulating Hormone</measure>
    <time_frame>Serum blood samples were collected for hormone measurements at the same time daily during the 7 day hormone free interval.</time_frame>
    <description>mean FSH on day 7 of the pill free interval</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">64</enrollment>
  <condition>Hypothalamic-pituitary-ovarian Axis, Gonadotropins, Ethinyl Estradiol, Contraceptive Efficacy</condition>
  <arm_group>
    <arm_group_label>Healthy reproductive age women</arm_group_label>
    <description>These volunteers were previously taking the oral contraceptives of interest for a minimum of 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>combined oral contraceptives</intervention_name>
    <arm_group_label>Healthy reproductive age women</arm_group_label>
    <other_name>ALESSE, LOESTRIN, NORDETTE, ORTHOCEPT, ORTHOCYCLEN, ORTHO NOVUM</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Healthy, reproductive age women 18 to 35 years old, who were seeking contraception from the
        general gynecology clinics of the LAC and USC Medical Center were recruited. The research
        team identified potential candidates who were taking one of 6 possible monophasic COC
        formulations. Informed consent was obtained from participants by the research staff. To be
        eligible for participation, women reported regular menstrual cycles prior to COCs, and had
        taken at least 3 cycles of the same monophasic COC prior to enrollment.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, reproductive age women

          -  18 to 35 years old,

          -  seeking contraception from the general gynecology clinics of the LAC and USC Medical
             Center w

          -  taking one of 6 possible monophasic COC formulations for at least 3 cycles prior to
             enrollment

          -  regular menstrual cycles prior to COCs

        Exclusion Criteria:

          -  Irregular bleeding

          -  bilateral oophorectomy

          -  amenorrhea

          -  hormone-sensitive cancer

          -  concurrent medications known to interfere with steroid metabolism (i.e., barbiturates,
             phenytoin, carbamazepine, ethosuximide, primidone, rifampin, tetracycline)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>LAC and USC Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>September 17, 2013</study_first_submitted>
  <study_first_submitted_qc>September 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 30, 2013</study_first_posted>
  <results_first_submitted>July 19, 2015</results_first_submitted>
  <results_first_submitted_qc>July 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 26, 2019</results_first_posted>
  <last_update_submitted>July 25, 2019</last_update_submitted>
  <last_update_submitted_qc>July 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Southern California</investigator_affiliation>
    <investigator_full_name>Frank Stanczyk</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pituitary Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Norinyl</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Contraceptives, Oral, Combined</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>clinic</recruitment_details>
      <pre_assignment_details>voluntary</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Healthy Reproductive Age Women</title>
          <description>These volunteers were previously taking the oral contraceptives of interest for a minimum of 3 months
combined oral contraceptives</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="64">completed prior to clinical trials submission</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="64">completed prior to clinical trials submission</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Healthy Reproductive Age Women</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="64"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" lower_limit="18" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Follicle-stimulating Hormone</title>
        <description>mean FSH on day 7 of the pill free interval</description>
        <time_frame>Serum blood samples were collected for hormone measurements at the same time daily during the 7 day hormone free interval.</time_frame>
        <population>Of note 1 person from the 20 and another from the 30 mcg EE groups hand significant loss of sample and poor processing due to limitations with processing and transport. As a result of this not all participants were able to contribute data for analysis</population>
        <group_list>
          <group group_id="O1">
            <title>20 mcg EE</title>
            <description>These volunteers were previously taking the oral contraceptives of interest for a minimum of 3 months</description>
          </group>
          <group group_id="O2">
            <title>30 mcg EE</title>
            <description>These volunteers were previously taking the oral contraceptives of interest for a minimum of 3 months</description>
          </group>
          <group group_id="O3">
            <title>35 mcg EE</title>
            <description>These volunteers were previously taking the oral contraceptives of interest for a minimum of 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Follicle-stimulating Hormone</title>
          <description>mean FSH on day 7 of the pill free interval</description>
          <population>Of note 1 person from the 20 and another from the 30 mcg EE groups hand significant loss of sample and poor processing due to limitations with processing and transport. As a result of this not all participants were able to contribute data for analysis</population>
          <units>milli international units per milliliter</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.01" spread="0.25"/>
                    <measurement group_id="O2" value="5.86" spread="0.55"/>
                    <measurement group_id="O3" value="6.38" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.88</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Slope</param_type>
            <param_value>0.02</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.57</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Slope</param_type>
            <param_value>0.63</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.9</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>t-test, 2 sided</method>
            <param_type>Slope</param_type>
            <param_value>0.83</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>0.78</dispersion_value>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Healthy Reproductive Age Women</title>
          <description>These volunteers were previously taking the oral contraceptives of interest for a minimum of 3 months
combined oral contraceptives</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="64"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Cho</name_or_title>
      <organization>University Reproductive Associates</organization>
      <phone>(201) 288-6330</phone>
      <email>michaelcho@nyc.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

